Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of trastuzumab (Zercepac) in HER2-positive breast cancer
ChiCTR2200059543Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: progression-free survival. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200059543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059543.